Lawrence A. Kenyon Buys 5,000 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) Stock

Outlook Therapeutics, Inc. (NASDAQ:OTLK) CFO Lawrence A. Kenyon purchased 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were purchased at an average price of $5.69 per share, for a total transaction of $28,450.00. Following the completion of the acquisition, the chief financial officer now owns 5,946 shares of the company’s stock, valued at approximately $33,832.74. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Outlook Therapeutics Stock Down 2.2 %

NASDAQ OTLK opened at $5.22 on Wednesday. The company’s 50 day moving average is $7.11 and its 200-day moving average is $7.75. Outlook Therapeutics, Inc. has a 12-month low of $4.34 and a 12-month high of $18.00. The firm has a market cap of $122.18 million, a P/E ratio of -0.46 and a beta of 0.64.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.23. Equities analysts expect that Outlook Therapeutics, Inc. will post -3.59 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Outlook Therapeutics in a report on Thursday, August 15th. Chardan Capital reiterated a “buy” rating and issued a $53.00 target price on shares of Outlook Therapeutics in a research note on Friday, August 16th. Finally, Ascendiant Capital Markets dropped their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Outlook Therapeutics currently has an average rating of “Buy” and a consensus target price of $48.20.

Institutional Trading of Outlook Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of OTLK. AQR Capital Management LLC bought a new stake in shares of Outlook Therapeutics in the second quarter valued at approximately $75,000. Squarepoint Ops LLC bought a new stake in Outlook Therapeutics during the 2nd quarter worth approximately $232,000. Susquehanna Fundamental Investments LLC bought a new stake in Outlook Therapeutics during the 2nd quarter worth approximately $303,000. LVW Advisors LLC bought a new stake in Outlook Therapeutics during the 2nd quarter worth approximately $352,000. Finally, Rosalind Advisors Inc. increased its holdings in Outlook Therapeutics by 44.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock worth $3,321,000 after acquiring an additional 138,225 shares during the period. Institutional investors own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.